Amplia Therapeutics (ASX:ATX) Short-Term Capital Lease Obligation : A$0.00 Mil (As of Sep. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Amplia Therapeutics Short-Term Capital Lease Obligation?

Amplia Therapeutics's Short-Term Capital Lease Obligation for the quarter that ended in Sep. 2023 was A$0.00 Mil.

Amplia Therapeutics's quarterly Short-Term Capital Lease Obligation increased from Sep. 2022 (A$0.00 Mil) to Mar. 2023 (A$0.08 Mil) but then declined from Mar. 2023 (A$0.08 Mil) to Sep. 2023 (A$0.00 Mil).

Amplia Therapeutics's annual Short-Term Capital Lease Obligation stayed the same from Mar. 2021 (A$0.00 Mil) to Mar. 2022 (A$0.00 Mil) but then increased from Mar. 2022 (A$0.00 Mil) to Mar. 2023 (A$0.08 Mil).

Amplia Therapeutics Short-Term Capital Lease Obligation Historical Data

The historical data trend for Amplia Therapeutics's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amplia Therapeutics Short-Term Capital Lease Obligation Chart

Amplia Therapeutics Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Short-Term Capital Lease Obligation

Get a 7-Day Free Trial

0.08

Amplia Therapeutics Semi-Annual Data
	Sep14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24
Short-Term Capital Lease Obligation	Get a 7-Day Free Trial															-	-	0.08	-	0.08

Amplia Therapeutics Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

Amplia Therapeutics Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Amplia Therapeutics's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Amplia Therapeutics (ASX:ATX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Amplia Therapeutics Ltd (ASX:ATX) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

INNMF:USA

Address

350 Queen Street, Level 17, Melbourne, VIC, AUS, 3000

Website

https://www.ampliatx.com

Amplia Therapeutics Ltd is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. Its molecule, AMP945 is a pure-play inhibitor, while the second molecule, AMP886, is a multi-action molecule that hits two other important cancer pathways - VEGFR3 and FLT3.

Amplia Therapeutics (ASX:ATX) Headlines

No Headlines